Pharmaceutical industry
Merck Receives FDA Approval for Extended Marketing Exclusivity of Pepcid
Merck & Co., Inc., a leading research-driven pharmaceutical company, has announced that the Food and Drug Administration (FDA) has granted six additional months of marketing exclusivity to Pepcid (famotidine) in response to a supplemental new drug application (sNDA) submitted by the company. This decision delays FDA approval of generic famotidine